Ablynx, Novo Nordisk deal

Ablynx and Novo Nordisk partnered to exclusively discover and develop Ablynx’s multispecific Nanobodies for use in an undisclosed disease area, with an option to expand to include a second Nanobody program.

Under the initial three-year research term, Ablynx, which is responsible for discovery of the Nanobodies, received EUR5 million ($5.3 million) up front and will receive up to EUR4 million ($4.3 million) in research funding. If Novo Nordisk exercises its option to the second program, it will pay Ablynx an exercise fee of EUR4 million. Ablynx is also eligible for development, regulatory and commercial milestones of up to EUR182 million ($193.5 million) per program, plus tiered royalties. ...